تخطَّ إلى المحتوى
دليل الأدوية المصري
تابع آخر تحديثات الأسعار على واتساب

سعر تارسيفا 100مجم 30 قرص 2026

Tarceva 100 mg 30 f.c. tabs

معلومات الدواء

التفاصيل الكاملة
عن الدواءAbout the medicine

Erlotinib 100 mg film-coated tablets, pack of 30 (Roche, distributed by Multipharma in Egypt).

Erlotinib 100 mg film-coated tablets, pack of 30 (Roche, distributed by Multipharma in Egypt).

دواعي الاستعمالUses
  • Metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations: first-line, maintenance, or after progression following at least one prior chemotherapy regimen.الفئة: AdultsDailyMed (US National Library of Medicine)
  • First-line treatment of locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.الفئة: AdultsDailyMed (US National Library of Medicine)
  • Metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations: first-line, maintenance, or after progression following at least one prior chemotherapy regimen.Population: AdultsDailyMed (US National Library of Medicine)
  • First-line treatment of locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.Population: AdultsDailyMed (US National Library of Medicine)
الآثار الجانبيةSide effects
  • Most common (>= 20%): rash, diarrhoea, anorexia, fatigue, dyspnoea, cough, nausea and vomiting.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
  • Most common (>= 20%): rash, diarrhoea, anorexia, fatigue, dyspnoea, cough, nausea and vomiting.International label, same formulation · DailyMed (US National Library of Medicine)
موانع الاستعمالContraindications
  • None (US label).نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
  • None (US label).International label, same formulation · DailyMed (US National Library of Medicine)
تحذيرات واحتياطاتWarnings & precautions
  • Interstitial lung disease (1.1%): withhold for new or progressive unexplained pulmonary symptoms; discontinue if ILD is diagnosed.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
  • Renal failure and hepatotoxicity (including hepatic failure and hepatorenal syndrome): monitor renal function, electrolytes and liver tests; withhold or discontinue for severe toxicity.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
  • Gastrointestinal perforation, bullous/exfoliative skin disorders and corneal perforation or severe ulceration: discontinue.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
عرض الكل (5)
  • Interstitial lung disease (1.1%): withhold for new or progressive unexplained pulmonary symptoms; discontinue if ILD is diagnosed.International label, same formulation · DailyMed (US National Library of Medicine)
  • Renal failure and hepatotoxicity (including hepatic failure and hepatorenal syndrome): monitor renal function, electrolytes and liver tests; withhold or discontinue for severe toxicity.International label, same formulation · DailyMed (US National Library of Medicine)
  • Gastrointestinal perforation, bullous/exfoliative skin disorders and corneal perforation or severe ulceration: discontinue.International label, same formulation · DailyMed (US National Library of Medicine)
Show all (5)
التداخلات الدوائيةDrug interactions
  • Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, ritonavir, voriconazole, grapefruit) or combined CYP3A4/CYP1A2 inhibitors (e.g. ciprofloxacin)Increase erlotinib exposure; avoid, or reduce the erlotinib dose if co-administration is unavoidable.DailyMed (US National Library of Medicine)
  • CYP3A4 inducers (e.g. rifampin, carbamazepine, phenytoin, phenobarbital, St John's wort)Decrease erlotinib exposure; increase the erlotinib dose if co-administration is unavoidable.DailyMed (US National Library of Medicine)
  • Cigarette smoking (CYP1A2 induction)Decreases erlotinib exposure; avoid smoking.DailyMed (US National Library of Medicine)
عرض الكل (4)
  • Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, ritonavir, voriconazole, grapefruit) or combined CYP3A4/CYP1A2 inhibitors (e.g. ciprofloxacin)Increase erlotinib exposure; avoid, or reduce the erlotinib dose if co-administration is unavoidable.DailyMed (US National Library of Medicine)
  • CYP3A4 inducers (e.g. rifampin, carbamazepine, phenytoin, phenobarbital, St John's wort)Decrease erlotinib exposure; increase the erlotinib dose if co-administration is unavoidable.DailyMed (US National Library of Medicine)
  • Cigarette smoking (CYP1A2 induction)Decreases erlotinib exposure; avoid smoking.DailyMed (US National Library of Medicine)
Show all (4)
الحمل والرضاعةPregnancy & breastfeeding
  • Can cause fetal harm based on animal data and mechanism; embryo-fetal lethality and abortion in rabbits at about 3 times human exposure. Advise pregnant women of the risk.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
  • No data on presence in human milk; advise not to breastfeed during treatment and for 2 weeks after the final dose.نشرة دولية لنفس التركيبة · DailyMed (US National Library of Medicine)
  • Can cause fetal harm based on animal data and mechanism; embryo-fetal lethality and abortion in rabbits at about 3 times human exposure. Advise pregnant women of the risk.International label, same formulation · DailyMed (US National Library of Medicine)
  • No data on presence in human milk; advise not to breastfeed during treatment and for 2 weeks after the final dose.International label, same formulation · DailyMed (US National Library of Medicine)
كيف يعمل الدواءHow it works
  • Reversibly inhibits EGFR (HER1) tyrosine kinase activity.
  • Erlotinib: Reversibly inhibits EGFR (HER1) tyrosine kinase activity.

المصادر

تعليقات

لا توجد تعليقات بعد. كن أول من يشارك تجربته مع هذا الدواء.

أضف تعليقًا

0/60

لا يُنشر أبدًا؛ للتواصل فقط إن لزم.

0/1000

من 20 إلى 1000 حرف. بدون روابط.

التعليقات للمعلومات العامة ولا تُعد نصيحة طبية. لا تذكر بيانات شخصية.